Institut für Biochemie, Universitätsklinikum RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
Author for correspondence (e-mail: mueller-newen{at}rwth-aachen.de)
Accepted 9 August 2005
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Cytokine receptor, Gp130, LIFR, Dimerization, FRET, BiFC
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Together with interferons and cytokines of the IL-10 family, the haematopoietic cytokines build up the large family of helical cytokines (Boulay et al., 2003). Whereas interferons and IL-10 family cytokines signal through class II cytokine receptors, the haematopoietic cytokines use class I cytokine receptors. The structural hallmark of these class I or haematopoietic cytokine receptors is a tandem array of fibronectin type III-like (FNIII) domains termed cytokine binding module (CBM) or cytokine receptor homology region (CHR) (Wells and de Vos, 1996
). The N-terminal FNIII domain is stabilized by four conserved cysteine residues forming two disulfide bonds, the C-terminal FNIII domain contains a highly conserved WSXWS motif. The extracellular part of `short cytokine receptors' such as the erythropoietin (Epo) receptor or the growth hormone (GH) receptor consists only of a single CBM. `Tall cytokine receptors' such as gp130 or the leukaemia inhibitory factor (LIF) receptor contain additional FNIII or Ig-like domains.
Class I and class II cytokine receptors signal through the Jak/STAT pathway (Ihle, 1995). The membrane proximal cytoplasmic part of these receptors is constitutively and stably associated with Janus tyrosine kinases (Jaks) (Giese et al., 2003
). Upon cytokine binding to the extracellular part of the receptor, the cytoplasmic Jaks become activated by tyrosine phosphorylation. The activated Jaks phosphorylate tyrosine residues in the membrane distal cytoplasmic part of the receptor and the phosphotyrosine motifs are docking sites for signalling molecules containing SH2 or PTB domains. Most importantly, signal transducer and activator of transcription (STAT) proteins are recruited by their SH2 domain to specific phosphotyrosine motifs. Subsequently the Jaks phosphorylate the STATs at a single tyrosine residue leading to the release of STAT dimers from the receptor and their translocation to the nucleus where they activate target genes.
How exactly cytokine binding leads to receptor activation, i.e. triggering of the Jak/STAT pathway is an unresolved issue. Much progress has been made in the understanding of the interaction of haematopoietic cytokines with their receptors. The growth hormone paradigm has been derived from the X-ray structure of GH bound to the soluble GH receptor (GHR) (de Vos et al., 1992). Two surface areas termed site I and site II of a single GH molecule bind to two identical receptor subunits leading to the idea that ligand-induced receptor dimerization is the main trigger for the signal transduction cascade. Studies on the related Epo/EpoR system revealed that an inactive EpoR dimer is formed by an artificial antagonistic peptide (Livnah et al., 1998
). Thus, receptor dimerization does not necessarily lead to receptor activation. This idea was supported by experimental evidence suggesting that the EpoR exists as a preformed, inactive receptor dimer in the plasma membrane (Livnah et al., 1999
). In this situation, instead of triggering dimerization, the ligand switches the receptor from an inactive to an active dimer conformation. Receptor pre-association has also been described for other receptors spanning the membrane only once (Jiang and Hunter, 1999
).
Epo is the only known ligand for the EpoR. Besides such monospecific receptors, shared haematopoietic cytokine receptors exist which recognize several cytokines (Boulanger and Garcia, 2004). Three receptor systems are known, that are based on a central shared receptor subunit. The common beta chain (ßc) is used by the cytokines IL-3, IL-5 and GM-CSF, the common gamma chain (
c) recognizes IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21 whereas gp130 is the most promiscuous cytokine receptor involved in the binding of nine different cytokines (Bravo and Heath, 2000
). These IL-6-type cytokines signal either through gp130 homodimers (IL-6, IL-11) or through heterodimers of gp130 and the LIFR (LIF, CNTF, CT-1, CLC, NP), heterodimers of gp130 and the OSMR (OSM) and heterodimers of gp130 and the IL-27R/WSX-1 (IL-27) (Heinrich et al., 2003
). In such a scenario a stable preformed gp130 homodimer would greatly facilitate IL-6 and IL-11 signalling but at the same time would prevent signalling by the cytokines that require receptor heterodimerization. Conversely, stable preformed heterodimers would discriminate against signalling through gp130 homodimers.
The extracellular part of gp130 consists of six domains: an Ig-like domain (D1) is followed by the CBM (D2 and D3) and three further FNIII domains (D4-D6) (Hibi et al., 1990). In LIF-induced heterodimerization with the LIFR, only the CBM of gp130 contacts LIF (Hammacher et al., 1998
; Timmermann et al., 2000
). The LIFR contributes mainly with its Ig-like domain to LIF binding (Owczarek et al., 1997
). Receptor assembly in response to IL-6 is more complicated. Activation of gp130 homodimers by IL-6 requires binding of IL-6 to a specific
-receptor (IL-6R
) (Taga et al., 1989
), which does not contribute to the intracellular signal transduction cascade. Cells that express gp130 but lack IL-6R
expression can be stimulated by the combination of IL-6 and soluble IL-6R
(sIL-6R
) (Taga et al., 1989
). The complex of IL-6R
or sIL-6R
bound to site I of IL-6 provides two gp130 binding sites (termed site II and site III). In the final hexameric receptor complex two IL-6/IL-6R
heterodimers are bound to the gp130 homodimer (Boulanger et al., 2003b
). One IL-6 molecule contacts with its site II the CBM of one gp130 and with its site III the Ig-like domain of the second gp130. The same is true in a reciprocal fashion for the second IL-6 molecule leading to a highly symmetrical complex.
In this report we investigate gp130 homodimerization and heterodimerization of gp130 with the LIFR in unstimulated and cytokine (IL-6 or LIF) stimulated cells. As discussed for other receptors (Jiang and Hunter, 1999), putative receptor/receptor interactions could be dominated by contacts of the transmembrane regions that require an intact plasma membrane. Furthermore, pre-association of receptors by weak protein-protein interactions could be disrupted by solubilization of the membrane. Therefore, we decided to study receptor oligomerization at the plasma membrane of single, intact cells by fluorescence resonance energy transfer (FRET) and bimolecular fluorescence complementation (BiFC). We found, that gp130 forms transient homodimers that are stabilized by addition of the ligand. Heterodimerization of gp130 with the LIFR, however, is mainly triggered by the ligand. We present a model of receptor assembly that takes into account the different ligand-binding characteristics of gp130 homodimers and gp130/LIFR heterodimers.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cloning of expression vectors
The expression vectors pSVLgp130-CFP, pSVLgp130/id-CFP and pSVLgp130/id-YFP were cloned as described elsewhere (Giese et al., 2003). The construct pSBCLIFR/id-CFP is based on the earlier described expression vector pSBCLIFR (Timmermann et al., 2000
) and encodes a cytoplasmically truncated LIFR protein in which Leu882 of the LIFR is followed by a Ser-Arg linker and Val2 of CFP. In the BiFC construct pSVLgp130/id-YC173, containing only the C-terminal half of YFP (amino acids 173-238), Asp173 of YFP immediately follows Pro668 of gp130. The BiFC constructs pSVLgp130/id-YN173 and pSBCLIFR/id-CN173 are derived from pSVLgp130/id-YFP and pSBCLIFR/id-CFP. pSVLgp130/id-YN173 and pSBCLIFR/id-CN173 contain the cDNA of N-terminal fragments (amino acids 2-172) of YFP (YN173) and CFP (CN173). The BiFC fragments of CFP and YFP were selected according to Hu and Kerppola (Hu and Kerppola, 2003
). YFP-IL-6 was cloned by inserting the cDNA encoding YFP (Invitrogen, USA) between the signal sequence for secretion of the protein and the sequence encoding mature human IL-6 (Fig. 1A). All constructs were verified by DNA sequencing.
|
SDS-PAGE and western blotting
Electrophoretically separated proteins were transferred to polyvinylidene difluoride membranes (PALL, Dreieich, Germany) by a semi-dry blotting procedure. The membrane was blocked with 10% bovine serum albumin, subsequently incubated with the antibodies as indicated in the figures and processed for chemiluminescence detection as described in the enhanced chemiluminescence manual (Amersham Biosciences, UK).
Immunofluorescence
Immunofluorescence staining of transfected COS-7 cells was carried out after formaldehyde fixation. The cells were blocked with PBS2+ (PBS with 1 mM MgCl2 and 0.1 mM CaCl2) containing 1% BSA for 30 minutes and then incubated with PBS2+ containing 0.1% BSA and the primary antibody (10 µg/ml) for 60 minutes. After washing twice with PBS2+ containing 0.1% BSA, the cells were incubated with a R-phycoerythrin-coupled secondary antibody at a 1:100 dilution in PBS2+ containing 0.1% BSA for 1 hour. After further washing with PBS2+ containing 0.1% BSA and afterwards with water, the slides were mounted with 10% (w/v) Mowiol (Calbiochem, USA), 25% (w/v) glycerin, 25% (v/v) water, 45% (v/v) 0.1 M Tris-HCl, pH 8.5.
Fixation of cells for FRET and BiFC detection
24 hours after transfection, cells were seeded on 18 mm glass coverslips and 48 hours after transfection cells were then fixed using 3% formaldehyde in PBS2+ (1 mM MgCl2, 0.1 mM CaCl2 in PBS) for 20 minutes. After fixation, cells were washed twice with PBS2+, incubated for 5 minutes with PBS2+ containing 50 mM NH4Cl, washed with PBS2+ and finally with water. The slides were mounted with Mowiol as described above. To support BiFC complementation, 30 hours after transfection the incubation temperature of Hek293T cells was decreased from 37°C to 30°C. After 18 hours of incubation at 30°C, the cells were fixed.
Confocal microscopy and live cell imaging
Confocal imaging was carried out on a Zeiss LSM 510 confocal microscope equipped with an argon-ion laser and a helium-neon laser (Zeiss, Jena, Germany). CFP and YFP signals were detected as described previously (Giese et al., 2003). Phycoerythrin (PE) fluorescence was detected using the 543 nm emission line of the helium-neon laser. A 543 nm dichroic mirror and a 560-640 nm bandpass filter completed the PE-beampath. For images of cells coexpressing CFP and YFP or CFP and PE the multi-track function of the LSM 510 was used. The images represent
1-µm-thick confocal slices of whole cells. If not otherwise noted, cells were examined with a 63x 1.2 NA Zeiss water immersion objective.
Live cell imaging was carried out with COS-7 cells transiently transfected using the DEAE-dextran method. Transfected cells were grown on 18 mm glass coverslips. 48 hours after transfection the coverslips were placed in a home-built perfusion chamber and flushed with DMEM supplemented with 10% FCS, 100 mg/l streptomycin, and 60 mg/l penicillin. To maintain 37°C during all image acquisition the perfusion chamber and the objective were attached to a thermostat.
FRET detection
For FRET detection between CFP and YFP, a variant of the beampath for CFP detection was used with a 458/514 nm main dichroic mirror, a 515 nm dichroic mirror and a 530-600 nm bandpass filter to detect YFP fluorescence on a second photodetector in parallel to the CFP signal (bandpass 470-490 nm). The pinhole adjustment resulted in a 1.5 µm confocal slice. The image resolution was 256x256 pixels and 12-bit with a zoom factor of 2.6. After five prebleach scans of a region of interest (ROI 1) at the plasma membrane of the selected fixed cell, YFP in ROI 1 was bleached using the 514 nm argon laser line with 40% of 25 mW maximum laser power (100% transmission) for 100 iterations. Directly after bleaching of YFP the fluorescence was sampled in five postbleach scans. An additional ROI on the plasma membrane (ROI 2) was monitored in parallel to ROI 1 but was not bleached in order to detect fluorescence fluctuations independent of bleaching. A third ROI (ROI 3) was placed outside the cell to measure background fluorescence. The settings for prebleach and recovery image scans were 40% of 25 mW and 5% transmission for the 458 nm argon laser line. All images were acquired under the same settings for gain, resolution and optical components. Average fluorescence intensities within ROIs were exported into Microsoft Excel (Microsoft, USA). In each time series, the intensities in ROI 1 and ROI 2 were background corrected using the fluorescence intensities of ROI 3. The FRET energy transfer efficiency (Ef) was calculated as described (Karpova et al., 2003). For qualitative FRET imaging, before and after bleaching of YFP the whole cell was scanned using separate beampaths for CFP and YFP detection and the multitrack function of the LSM 510 as described under confocal microscopy.
BiFC detection
For measurement of YFP fluorescence after complementation of gp130/id-YC173 and gp130/id-YN173 the YFP beampath was used as described under confocal microscopy. According to Hu and Kerppola (Hu and Kerppola, 2003) complementation of the C-terminal YFP fragment YC173 with the N-terminal CFP fragment CN173 generates a fluorophore with an excitation maximum at 466 nm and an emission maximum at 497 nm. Therefore, fluorescence resulting from complementation of gp130/id-YC173 and LIFR/id-CN173 was detected using the 458 nm line of the argon laser in combination with a 458 nm main dichroic mirror and a 475 nm longpass filter. The spectra of the dyes were recorded with the Meta-detector (Zeiss, Jena, Germany) of the confocal microscope.
Images for quantitative BIFC analysis were collected using a 20x 0.75 NA Zeiss objective. The pinhole diameter resulted in 2 µm confocal slices. The images have a resolution of 512x512 pixels and a 12-bit intensity scale. All images were acquired under the same settings.
BiFC was also analysed by FACS. After fluorescence complementation, cells were washed with PBS and resuspended in PBS containing 5% FCS and 15 mM sodium azide on ice. FACS analysis was performed with a Facscalibur (Becton-Dickinson) using the 488 nm laser for excitation and a 515-545 nm bandpass filter for detection.
Evaluation of quantitative BiFC data
Images for quantitative BiFC analysis were filtered twice using a 7x7 pixel lowpass filter matrix. After subtraction of background fluorescence of image areas that were not covered with cells, the pixel quantities of the different fluorescence intensities of resulting images were exported into Microsoft Excel. The number of pixels representing BiFC fluorescence intensities was then related to the amount of all pixels with fluorescence intensities produced by BiFC or autofluorescence of cells.
For all quantitative FRET and BiFC analyses, significance was calculated using one-way ANOVA including a Tamhane post-hoc test. Values of P<0.05 were considered significant.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
The integrity of the gp130 deletion constructs was verified by the use of monoclonal antibodies that had been previously mapped to individual gp130 domains (Wijdenes et al., 1995). Whereas gp130/id-CFP is recognized by all three antibodies, antibodies directed against D1 and the CBM of gp130 fail to detect the corresponding deletion constructs (Fig. 2A). Furthermore, the immunofluorescence reveals that deletion of individual domains does not interfere with gp130 surface expression. Upon overexpression of gp130/id-CFP and the deletion constructs in COS-7 cells only the wild-type extracellular region recruits YFP-IL-6/sIL-6R
complexes to the plasma membrane (Fig. 2B). Both deletion constructs failed to efficiently bind the ligand (Fig. 2C,D). Recruitment of IL-6/sIL-6R
-complexes to monomeric gp130 would require binding of either IL-6 site II to the CBM of gp130 or IL-6 site III to D1 of gp130 as a first binding event. Neither of the two gp130 epitopes on its own efficiently recruits IL-6/sIL-6R
complexes to the plasma membrane. Thus, preformation of gp130 homodimers would strongly increase the sensitivity of gp130 towards IL-6.
Detection of FRET at the plasma membrane by acceptor photobleaching
We adapted a previously published method (Karpova et al., 2003) to measure FRET between CFP and YFP by acceptor (YFP) photobleaching at the plasma membrane of single cells. Upon acceptor bleaching, the FRET donor (CFP) cannot transfer its energy to the acceptor any more and therefore its fluorescence increases. As a membrane-bound FRET positive control we fused a CFP-YFP in tandem to gp130 (gp130/id-C/YFP). This construct can be detected at the plasma membrane of transfected HEK293T cells in the YFP as well as in the CFP channel of the confocal microscope (Fig. 3A, left images). Selective bleaching of the YFP moiety with the 514 nm laser results in loss of YFP fluorescence and an increase in CFP fluorescence (Fig. 3A). The fluorescence intensities within the regions of interests (ROIs; e.g. white squares in Fig. 3A) of a series of images before and after bleaching are shown in the graph in Fig. 3B. The FRET efficiency can be calculated from the increase in CFP fluorescence after YFP bleaching (see Materials and Methods).
|
In a series of measurements, the FRET efficiencies of the FRET positive control (gp130/id-C/YFP) were compared with a FRET negative control (expression of gp130/id-CFP alone). A mean FRET efficiency of 29.8±3.6% was calculated for the gp130/id-C/YFP construct whereas the FRET negative control yielded values close to zero (Fig. 3C,D). The fluorescence within the ROI before bleaching is a measure for the expression level of the fluorescent fusion proteins at the plasma membrane. The FRET efficiency of individual experiments is given as a function of the initial fluorescence (Fig. 3C). Notably, the FRET efficiency of gp130/id-C/YFP does not depend on the expression level.
Analysis of gp130 homodimerization and gp130/LIFR heterodimerization by FRET
To detect gp130 homodimerization by FRET gp130/id-YFP and gp130/id-CFP expression vectors were cotransfected into HEK293T cells. For FRET analysis, only those cells where YFP expression equals or moderately exceeds CFP expression were considered (Fig. 4A, left diagram). The ratio of YFP intensity/CFP intensity of the gp130/id-C/YFP construct (not shown) providing equimolar YFP and CFP concentrations was used as a standard. A significant FRET signal could be detected which does not change upon stimulation with IL-6/sIL-6R complexes (Fig. 4A,B). The FRET signal slightly increases with elevated receptor expression (Fig. 4A, right diagram). The FRET approach is blind for gp130 homodimers with identical fluorophores and detects only dimers of gp130/id-YFP with gp130/id-CFP. Simple mendelian arithmetic revealed that this effect lowers the measured FRET values by 50%. This fact is considered in the bar chart (Fig. 4B) by depicting the hypothetical FRET values for exclusive YFP/CFP heterodimerization as dashed bars.
|
In a similar approach, heterodimerization of gp130 with the LIFR was studied by coexpression of gp130/id-YFP with LIFR/id-CFP. The cytoplasmic part of the LIFR/id construct is truncated after Leu882 leading to deletion of the internalization motif (Thiel et al., 1999) and enhanced surface expression. Again, only those cells were considered where YFP expression equals or moderately exceeds CFP expression (Fig. 4C, left panel) As in the case of gp130 homodimerization, a FRET signal could be detected in unstimulated cells (Fig. 4C,D). As the two receptors are fused to different fluorophores, every gp130/LIFR heterodimer can be detected by the FRET approach. Most interestingly, the FRET signal strongly increases upon stimulation with LIF, indicating that the formation of gp130/LIFR heterodimers is induced by LIF (Fig. 4C,D). The FRET efficiency after LIF stimulation is in the same order of magnitude as the `hypothetical' FRET efficiency of the gp130 homodimer (compare Fig. 4B, dashed bars and 4D). Taking this into account, in unstimulated cells gp130 preferentially forms gp130 homodimers. FRET efficiency of the gp130/LIFR heterodimer is independent of the expression levels (Fig. 4C, right panel).
Analysis of gp130 homodimerization and gp130/LIFR heterodimerization by BiFC
FRET does not discriminate between transient and stable interactions whereas the recently developed method of bimolecular fluorescence complementation (BiFC) detects predominantly stable protein-protein interactions (Hu et al., 2002). The BiFC method is based on the phenomenon that matching non-fluorescent `halves' of fluorescent proteins can complement each other to form the intact fluorophore. For complementation to occur, an interaction of the halves is required that is in the range of several seconds (Hu et al., 2002
). The affinity of the halves for each other is very low and therefore fluorescence complementation increases considerably by fusion partners that bring them into close proximity.
Gp130 was fused to the N-terminal half (gp130/id-YN173) or the C-terminal half of YFP (gp130/id-YC173). Cells were cotransfected with both constructs or with a single construct (gp130/id-YC173) as a negative control. As a first approach, we measured BiFC by FACS analysis. As reported previously (Kanno et al., 2004), the shifts of the cell populations are rather small owing to the low efficiency of fluorescence complementation. We detected a low BiFC fluorescence (Fig. 5A, dark grey) above background (light grey) in unstimulated cells that increased upon stimulation with IL-6/sIL-6R
(black). In the same manner, heterodimerization of gp130 with the LIFR was analysed by cotransfection of gp130/id-YC173 and LIFR/id-CN173. Upon complementation, a YFP-CFP hybrid fluorophore is formed with specific spectral properties (Hu and Kerppola, 2003
) which do not perfectly fit to the excitation/detection characteristics of a standard FACS device. Therefore, the shift of the population is even lower than in the case of gp130 BiFC. Nevertheless, a slight increase in fluorescence upon LIF stimulation is observed (Fig. 5D).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
This interpretation is supported by our studies on IL-6/sIL-6R binding to gp130 deletion mutants. From the crystal structure of the hexameric IL-6/sIL-6R
/sgp130 complex (Boulanger et al., 2003b
) it is evident that a single IL-6/sIL-6R
complex contacts two gp130 molecules. Site II of the IL-6/sIL-6R
complex binds to the CBM (D2, D3) of one gp130 molecule, site III of the same IL-6/sIL-6R
complex binds to D1 of the second gp130 molecule of the hexameric complex. As a consequence of gp130 monomers in the plasma membrane, in a first binding event IL-6/sIL-6R
complexes would bind either to D1 or to the CBM of a single gp130 molecule. Our experiments with the respective deletion mutants show that neither of these binding epitopes alone efficiently recruits IL-6/sIL-6R
-complexes to the plasma membrane (Fig. 6c). Thus, preformation of gp130 homodimers would greatly strengthen IL-6 sensing by the receptor by enabling IL-6/IL-6R
complexes to bind to D1 and the CBM of two gp130 molecules simultaneously. This activation model requires that the preformed gp130 homodimers do not initiate signal transduction. Indeed, previous studies from our group have shown that dimerization of gp130 is not sufficient for signalling but that a defined conformation of the gp130 homodimer has to be adjusted by the ligand for signalling to occur (Greiser et al., 2002
; Kurth et al., 2000
; Müller-Newen et al., 2000
).
Considering that in the case of ligand-independent pre-association there is no active involvement of the ligand in receptor dimerization, the ligand seems to be more important for complex stabilization and activation by a conformational change. If, as in the hexameric IL-6 receptor complex, several receptor chains constitute the complex, then pre-association represents a simplified method of complex formation. Complex preformation leads to greater ligand sensitivity because it prevents dissociation of the ligand from an intermediate low-affinity complex.
The tendency of LIFR to form heterodimers with gp130 in the absence of the ligand is rather low as FRET between CFP-tagged LIFR and YFP-tagged gp130 strongly increases upon LIF treatment. In line with this finding, BiFC between tagged LIFR and gp130 constructs increases significantly upon stimulation. Ligand-induced heterodimerization of LIFR and gp130 requires that LIFR or gp130 alone has a significant affinity to LIF. Binding of LIF to one receptor must have a sufficient half-life enabling this complex to encounter the second receptor by diffusion. In a recent study, it has been described that both gp130 and LIFR have measurable affinities to LIF (Boulanger et al., 2003a). As the affinity of LIF to the LIFR (Kd=1 nM) is higher than the affinity to the CBM of gp130 (Kd=80 nM), LIF binding to the LIFR might be the preferential first step in LIF signalling (Fig. 6, lower panel).
It is tempting to speculate how the other receptors involved in IL-6-type cytokine signalling fit into the scenario depicted in Fig. 6. It could be a general phenomenon that heterodimerization of gp130 with a second signal transducing receptor is triggered by the ligand. Thus, one would expect that heterodimerization of gp130 with the OSMR in response to OSM or of gp130 with the IL-27R/WSX-1 in response to IL-27 is ligand induced. At least for OSM it is known that it binds with sufficiently low affinity to gp130 alone (Kd=8 nM) (Gearing et al., 1992).
Signalling through gp130 homodimers requires binding of the cytokine to an -receptor subunit that does not contribute to signalling. IL-6 binds to IL-6R
and IL-11 binds to IL-11R
. The membrane-bound
-receptors can be replaced by the corresponding soluble receptors. Therefore, pre-association of these receptors with gp130 is not a strict requirement for signalling. Nevertheless, one could imagine a pre-association of the membrane-bound
-receptor with gp130. So far, only preformed IL-6R
homodimers have been described (Schuster et al., 2003
).
Membrane-bound receptors are not the only preformed components of the Jak/STAT signalling pathway. It is well established that Janus kinases constitutively (Ihle, 1995) and stably (Giese et al., 2003
) associate with cytokine receptors. In addition, proteins downstream of the receptors seem to exist in preformed complexes. Recent crystallographic evidence (Mao et al., 2005
) supported the notion of STAT dimers formed prior to cytokine stimulation. Activation of STATs by tyrosine phosphorylation leads to rearrangement of the dimer and its stabilization. Thus, pre-association of signalling proteins seems to be a general mechanism to increase the sensitivity, specificity and speed of signalling pathways. The underlying protein-protein interactions are potential targets for the development of new drugs in order to treat diseases caused by dysregulated signal transduction pathways.
![]() |
Acknowledgments |
---|
![]() |
Footnotes |
---|
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Boulanger, M. J. and Garcia, K. C. (2004). Shared cytokine signaling receptors: structural insights from the gp130 system. Adv. Protein Chem. 68, 107-146.[Medline]
Boulanger, M. J., Bankovich, A. J., Kortemme, T., Baker, D. and Garcia, K. C. (2003a). Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol. Cell 12, 577-589.[CrossRef][Medline]
Boulanger, M. J., Chow, D., Brevnova, E. E. and Garcia, K. C. (2003b). Hexameric structure and assembly of the interleukin-6/IL-6 -receptor/gp130 complex. Science 300, 2101-2104.
Boulay, J. L., O'Shea, J. J. and Paul, W. E. (2003). Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 19, 159-163.[CrossRef][Medline]
Bravo, J. and Heath, J. K. (2000). Receptor recognition by gp130 cytokines. EMBO J. 19, 2399-2411.
Chan, F. K., Chun, H. J., Zheng, L., Siegel, R. M., Bui, K. L. and Lenardo, M. J. (2000). A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288, 2351-2354.
Damjanovich, S., Bene, L., Matko, J., Alileche, A., Goldman, C. K., Sharrow, S. and Waldmann, T. A. (1997). Preassembly of interleukin 2 (IL-2) receptor subunits on resting Kit 225 K6 T cells and their modulation by IL-2, IL-7, and IL-15: a fluorescence resonance energy transfer study. Proc. Natl. Acad. Sci. USA 94, 13134-13139.
de Vos, A. M., Ultsch, M. and Kossiakoff, A. A. (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312.[Medline]
Dittrich, E, Haft, C. R., Muys, L., Heinrich, P. C. and Graeve, L. (1996). A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. J. Biol. Chem. 271, 5487-5494.
Gearing, D. P., Comeau, M. R., Friend, D. J., Gimpel, S. D., Thut, C. J., McGourty, J., Brasher, K. K., King, J. A., Gillis, S., Mosley, B. et al. (1992). The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255, 1434-1437.[Medline]
Giese, B., Au-Yeung, C.-K., Herrmann, A., Diefenbach, S., Haan, C., Küster, A., Wortmann, S. B., Roderburg, C., Heinrich, P. C., Behrmann, I. et al. (2003). Long-term association of the cytokine receptor gp130 and the Janus kinase Jak1 revealed by FRAP analysis. J. Biol. Chem. 278, 39205-39213.
Greiser, J. S., Stross, C., Heinrich, P. C., Behrmann, I. and Hermanns, H. M. (2002). Orientational constraints of the gp130 intracellular juxtamembrane domain for signaling. J. Biol. Chem. 277, 26959-26965.
Hammacher, A., Richardson, R. T., Layton, J. E., Smith, D. K., Angus, L. J. L., Hilton, D. J., Nicola, N. A., Wijdenes, J. and Simpson, R. J. (1998). The immunoglobulin-like module of gp130 is required for signaling by interleukin-6 but not by leukemia inhibitory factor. J. Biol. Chem. 273, 22701-22707.
Heinrich, P. C., Behrmann, I., Haan, S., Hermanns, H. M., Müller-Newen, G. and Schaper, F. (2003). Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374, 1-20.[CrossRef][Medline]
Helle, M., Boeije, L., de Groot, E., de Vos, A. and Aarden, L. (1991). Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J. Immunol. Meth. 138, 47-56.[CrossRef][Medline]
Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T. and Kishimoto, T. (1990). Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63, 1149-1157.[CrossRef][Medline]
Hu, C. D. and Kerppola, T. K. (2003). Simultaneous visualization of multiple protein interactions in living cells using multicolor fluorescence complementation analysis. Nat. Biotechnol. 21, 539-545.[CrossRef][Medline]
Hu, C. D., Chinenov, Y. and Kerppola, T. K. (2002). Visualization of interactions among bZIP and Rel family proteins in living cells using bimolecular fluorescence complementation. Mol. Cell 9, 789-798.[CrossRef][Medline]
Ihle, J. N. (1995). Cytokine receptor signaling. Nature 377, 591-594.[CrossRef][Medline]
Jiang, G. and Hunter, T. (1999). Receptor signaling: when dimerization is not enough. Curr. Biol. 9, R568-R571.[CrossRef][Medline]
Kanno, T., Kanno, Y., Siegel, R. M., Jang, M. K., Lenardo, M. J. and Ozato, K. (2004). Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 13, 33-43.[CrossRef][Medline]
Karpova, T. S., Baumann, C. T., He, L., Wu, X., Grammer, A., Lipsky, P., Hager, G. L. and McNally, J. G. (2003). Fluorescence resonance energy transfer from cyan to yellow fluorescent protein detected by acceptor photobleaching using confocal microscopy and a single laser. J. Microsc. 209, 56-70.[CrossRef][Medline]
Kurth, I., Horsten, U., Pflanz, S., Timmermann, A., Küster, A., Dahmen, H., Tacken, I., Heinrich, P. C. and Müller-Newen, G. (2000). Importance of the membrane-proximal extracellular domains for activation of the signal transducer glycoprotein 130. J. Immunol. 164, 273-282.
Livnah, O., Johnson, D. L., Stura, E. A., Farrell, F. X., Barbone, F. P., You, Y., Liu, K. D., Goldsmith, M. A., He, W., Krause, C. D. et al. (1998). An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat. Struct. Biol. 5, 993-1004.[CrossRef][Medline]
Livnah, O., Stura, E. A., Middleton, S. A., Johnson, D. L., Jolliffe, L. K. and Wilson, I. A. (1999). Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283, 987-990.
Mao, X., Ren, Z., Parker, G. N., Sondermann, H., Pastorello, M. A., Wang, W., McMurray, J. S., Demeler, B., Darnell, J. E., Jr and Chen, X. (2005). Structural bases of unphosphorylated STAT1 association and receptor binding. Mol. Cell 17, 761-771.[CrossRef][Medline]
Müller-Newen, G., Küster, A., Wijdenes, J., Schaper, F. and Heinrich, P. C. (2000). Studies on the IL-6-type cytokine signal transducer gp130 reveal a novel mechanism of receptor activation by monoclonal antibodies. J. Biol. Chem. 275, 4579-4586.
Owczarek, C. M., Zhang, Y., Layton, M. J., Metcalf, D., Roberts, B. and Nicola, N. A. (1997). The unusual species cross-reactivity of the leukemia inhibitory factor receptor alpha-chain is determined primarily by the immunoglobulin-like domain. J. Biol. Chem. 272, 23976-23985.
Robb, L., Li, R., Hartley, L., Nandurkar, H. H., Koentgen, F. and Begley, C. G. (1998). Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation. Nat. Med. 4, 303-308.[CrossRef][Medline]
Schuster, B., Meinert, W., Rose-John, S. and Kallen, K. J. (2003). The human interleukin-6 (IL-6) receptor exists as a preformed dimer in the plasma membrane. FEBS Lett. 538, 113-116.[CrossRef][Medline]
Stewart, C. L., Kaspar, P., Brunet, L. J., Bhatt, H., Gadi, I., Kontgen, F. and Abbondanzo, S. J. (1992). Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359, 76-79.[CrossRef][Medline]
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T. and Kishimoto, T. (1989). Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58, 573-581.[CrossRef][Medline]
Thiel, S., Behrmann, I., Timmermann, A., Dahmen, H., Müller-Newen, G., Schaper, F., Tavernier, J., Pitard, V., Heinrich, P. C. and Graeve, L. (1999). Identification of a Leu-Ile interalization motif within the cytoplasmic domain of the leukaemia inhibitory factor receptor. Biochem. J. 339, 15-19.[CrossRef][Medline]
Timmermann, A., Pflanz, S., Grötzinger, J., Küster, A., Kurth, I., Pitard, V., Heinrich, P. C. and Müller-Newen, G. (2000). Different epitopes are required for gp130 activation by interleukin-6, oncostatin M and leukemia inhibitory factor. FEBS Lett. 468, 120-124.[CrossRef][Medline]
Wells, J. A. and de Vos, A. M. (1996). Hematopoietic receptor complexes. Annu. Rev. Biochem. 65, 609-634.[CrossRef][Medline]
Wijdenes, J., Heinrich, P. C., Müller-Newen, G., Roche, C., Zong-Jiang, G., Clement, C. and Klein, B. (1995). Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur. J. Immunol. 25, 3474-3481.[Medline]
Yoshida, K., Taga, T., Saito, M., Suematsu, S., Kumanogoh, A., Tanaka, T., Fujiwara, H., Hirata, M., Yamagami, T., Nakahata, T. et al. (1996). Targeted disruption of gp130, the common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc. Natl. Acad. Sci. USA. 93, 407-411.